Clinical Trial: A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older

U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07908654) titled 'A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older' on Oct. 26.

Brief Summary: This is a randomized, observer-blinded, placebo-controlled Phase III clinical trial to evaluate efficacy, immunogenicity and safety of the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in participants aged 60 years and older.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Respiratory Syncytial Virus (RSV) Respiratory Syncytial Virus (RSV) Infection RSV Vaccine

Intervention: BIOLOGICAL: LYB005

0.5 mL per dose.

BIOLOGICAL: Placebo...